These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 17956710)

  • 1. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.
    Cho D; Signoretti S; Dabora S; Regan M; Seeley A; Mariotti M; Youmans A; Polivy A; Mandato L; McDermott D; Stanbridge E; Atkins M
    Clin Genitourin Cancer; 2007 Sep; 5(6):379-85. PubMed ID: 17956710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
    Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
    Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
    Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J
    BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha.
    Figlin RA; de Souza P; McDermott D; Dutcher JP; Berkenblit A; Thiele A; Krygowski M; Strahs A; Feingold J; Boni J; Hudes G
    Cancer; 2009 Aug; 115(16):3651-60. PubMed ID: 19526589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status and future directions of molecular markers in renal cell carcinoma.
    Rini BI
    Curr Opin Urol; 2006 Sep; 16(5):332-6. PubMed ID: 16905977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.
    Pantuck AJ; Seligson DB; Klatte T; Yu H; Leppert JT; Moore L; O'Toole T; Gibbons J; Belldegrun AS; Figlin RA
    Cancer; 2007 Jun; 109(11):2257-67. PubMed ID: 17440983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease.
    Montani M; Heinimann K; von Teichman A; Rudolph T; Perren A; Moch H
    Am J Surg Pathol; 2010 Jun; 34(6):806-15. PubMed ID: 20431476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study.
    Reungwetwattana T; Molina JR; Mandrekar SJ; Allen-Ziegler K; Rowland KM; Reuter NF; Luyun RF; Dy GK; Marks RS; Schild SE; Jett JR; Adjei AA
    J Thorac Oncol; 2012 May; 7(5):919-22. PubMed ID: 22722792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2.
    Harada K; Miyake H; Kumano M; Fujisawa M
    Br J Cancer; 2013 Oct; 109(9):2389-95. PubMed ID: 24091619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer.
    Stewart GD; O'Mahony FC; Laird A; Rashid S; Martin SA; Eory L; Lubbock AL; Nanda J; O'Donnell M; Mackay A; Mullen P; McNeill SA; Riddick AC; Aitchison M; Berney D; Bex A; Overton IM; Harrison DJ; Powles T
    Eur Urol; 2014 Nov; 66(5):956-63. PubMed ID: 24821582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.
    Motzer RJ; Hutson TE; Hudes GR; Figlin RA; Martini JF; English PA; Huang X; Valota O; Williams JA
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):739-50. PubMed ID: 25100134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and predictive biomarkers in renal cell carcinoma.
    Vickers MM; Heng DY
    Target Oncol; 2010 Jun; 5(2):85-94. PubMed ID: 20582732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
    Malizzia LJ; Hsu A
    Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma].
    Ravaud A; Bernhard JC; Gross-Goupil M; Digue L; Ferriere JM
    Bull Cancer; 2010; 97():45-51. PubMed ID: 20418203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular markers to predict response to therapy.
    Garcia-Donas J; Rodriguez-Antona C; Jonasch E
    Semin Oncol; 2013 Aug; 40(4):444-58. PubMed ID: 23972708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).
    Choueiri TK; Cheng S; Qu AQ; Pastorek J; Atkins MB; Signoretti S
    Urol Oncol; 2013 Nov; 31(8):1788-93. PubMed ID: 23141780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VHL mutations and dysregulation of pVHL- and PTEN-controlled pathways in multilocular cystic renal cell carcinoma.
    von Teichman A; Compérat E; Behnke S; Storz M; Moch H; Schraml P
    Mod Pathol; 2011 Apr; 24(4):571-8. PubMed ID: 21151099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Candidate tumor suppressor and pVHL partner Jade-1 binds and inhibits AKT in renal cell carcinoma.
    Zeng L; Bai M; Mittal AK; El-Jouni W; Zhou J; Cohen DM; Zhou MI; Cohen HT
    Cancer Res; 2013 Sep; 73(17):5371-80. PubMed ID: 23824745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma.
    Phuoc NB; Ehara H; Gotoh T; Nakano M; Kamei S; Deguchi T; Hirose Y
    Oncol Rep; 2008 Sep; 20(3):525-30. PubMed ID: 18695901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.